This Cancer Center Support Grant application from the University of Pittsburgh Cancer Institute, an NCI-designated Comprehensive Cancer Center, seeks support for years 22-26. The UPCI is organized as a matrix center that integrates cancer research, clinical care, and cancer outreach across the University of Pittsburgh and its affiliated health system, UPMC. The UPCI includes 348 members from 37 academic departments who have come together to work to reduce the burden of cancer through cancer-related basic, translational, clinical, behavioral, epidemiological, prevention and control research. Total annual extramural cancer research funding (direct costs) to UPCI was $109.5 million (peer-reviewed $95M, non-peer-reviewed $14.5M) on October 1, 2009 of which $42.5M was received from the National Cancer Institute. The commitment of UPCI to transdisciplinary cancer research is exemplified by the fact that its members lead three SPORE grants (lung, head and neck, and skin cancers), eight cancer-focused P01s, two Early Detection Research Network grants, and a phase I U01. The impact of the cancer research driven by UPCI and its members can be seen in the more than 4,400 unique publications by UPCI investigators from 2004-2009 of which 45% represent collaborative efforts (17% intra-programmatic, 20% inter-programmatic, and 8% both). The integration of investigators at the main University of Pittsburgh campus with clinicians from a unique clinical care network encompassing about 40 UPMC community cancer centers across Western Pennsylvania has enabled enhanced patient access to clinical trials throughout our catchment area in a highly productive way. In 2008 a total of 11,484 patients were entered in the cancer registry. During that same year 1,158 and 2,508 patients entered interventional and non-interventional clinical trials, respectively. It is noteworthy that in 2008 30% of accruals to interventional trials were to investigator-initiated trials and 40% of accruals to interventional trials took place at UPMC community cancer centers. This renewal application requests support for twelve scientific research Programs, fifteen Shared Facilities, Protocol-Specific Research Support, Protocol Review and Monitoring System, planning and evaluation activities, developmental funds, senior leadership, staff investigators, and administration.

Public Health Relevance

UPCI is a comprehensive Cancer Center focused on cancer research, education, and care. UPCI laboratory and clinical investigators work closely together to identify improved approaches for cancer prevention, diagnosis and treatment with the common goal of reducing the burden of cancer and improving cancer care for patients who are diagnosed with this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA047904-26S3
Application #
8795827
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (M1))
Program Officer
Marino, Michael A
Project Start
1997-09-10
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$307,655
Indirect Cost
$96,629
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Jin, Tao; Iordanova, Bistra; Hitchens, T Kevin et al. (2018) Chemical exchange-sensitive spin-lock (CESL) MRI of glucose and analogs in brain tumors. Magn Reson Med 80:488-495
Samal, Jasmine; Kelly, Samantha; Na-Shatal, Ali et al. (2018) Human immunodeficiency virus infection induces lymphoid fibrosis in the BM-liver-thymus-spleen humanized mouse model. JCI Insight 3:
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Leibowitz, Brian J; Yang, Liheng; Wei, Liang et al. (2018) Targeting p53-dependent stem cell loss for intestinal chemoprotection. Sci Transl Med 10:
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Retseck, Janet; Nasr, Alexis; Lin, Yan et al. (2018) Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med 16:184
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Samanta, Suman K; Lee, Joomin; Hahm, Eun-Ryeong et al. (2018) Peptidyl-prolyl cis/trans isomerase Pin1 regulates withaferin A-mediated cell cycle arrest in human breast cancer cells. Mol Carcinog 57:936-946
Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713
Persky, Michael J; Albergotti, William G; Rath, Tanya J et al. (2018) Positive Margins by Oropharyngeal Subsite in Transoral Robotic Surgery for T1/T2 Squamous Cell Carcinoma. Otolaryngol Head Neck Surg 158:660-666

Showing the most recent 10 out of 1187 publications